FDA Panel says obesity drugs need cardiac testing
SILVER SPRING, USA (Reuters) – A panel of advisers said that heart for new studies should require drugs against obesity, possibly adding a new obstacle in the way of its adoption. The food and drug administration panel of United States ( FDA) voted 17 to 6 that regulators should forcing companies to conduct studies of heart impact to sell their drugs in United States, even if the clinical trials do not show initially evidence of risk heart. However, the panel did not discuss even if the evidence should be out before or after approval. The news could affect Arena Pharmaceuticals Vivus Inc. Inc and Orexigen Therapeutics Inc, which are competing for bring the first drug against obesity to market more of a...
Read More